Price Target Analysis Cytori Therapeutics, Inc. (CYTX)

Lloyd Doyle
January 13, 2018

The volume on 11-Jan-18 appeared at 6.82 million contracts compared with 1.09 million shares per day average we have seen for the past 90 days. It has a market cap of $7.69 Million. The RSI oscillates between zero and 100. Also, a -75.75% overturn in Cytori Therapeutics, Inc. (CYTX) is at 57.88. Its minimum price target estimates has been figured out at $0.5 while the maximum price target forecast is established at $5. The trading of the day started with the price of the stock at $50.95. According to today's trading volume Cytori Therapeutics, ABOVE its 20-Day Avg. volume with the stock showing ABOVE Abnormal volume in the past 150 days. It helps you quickly get a picture of where Wall Street stands on a stock without reading huge research reports. The ATR is fairly simple to calculate and only needs historical price data. For the current year the company's revenue estimates are $7.63 Million compared to low analyst estimates of $6.88 Million and high estimates of $8.4 Million according to 3 number of analysts. This shows a surprise factor of 12.5 percent. Consensus earnings estimates are far from ideal, but they are watched by many investors and play an important role in measuring the appropriate valuation for a stock. The stock was sold at an average price of $0.34, for a total transaction of $24,694.20. These analysts have also projected a Low Estimate of $-0.07/share and a High Estimate of $-0.04/share.

Cytori Therapeutics, Inc. (NASDAQ:CYTX)'s earnings per share has been growing at a 32.5 percent rate over the past 5 year when average revenue increase was noted as 2.6 percent. The company reported the earnings of $-0.14/Share in the last quarter where the estimated EPS by analysts was $-0.16/share.

How Company Returns Shareholder's Value? It is the "top line" or "gross income" figure from which costs are subtracted to determine net income.

Cytori Therapeutics (NASDAQ:CYTX)'s revenue estimates for the current quarter are $2.74 Million according to 3 number of analysts, for the current quarter the company has high revenue estimates of $3.5 Million in contradiction of low revenue estimates of $2 Million. The high and low revenue estimates for the current quarter are $2.79 Million and $2.78 Million, respectively.

A moving average (MA) is a trend-following or lagging indicator because it is based on past prices. There are advantages to using a moving average in your trading, as well options on what type of moving average to use.

Analysts often look at short interest, or the number of shares now being shorted by investors, to aid in their outlook for a particular stock. Angled up and price is moving up (or was recently) overall, angled down and price is moving down overall, moving sideways and the price is likely in a range. The primary measure of volatility used by traders and analysts is standard deviation. 0 analysts gave its stock an Outperform rating. Of the analysts surveyed by Reuters that track SunPower Corporation 7 of them rate its stock a hold. Cytori Therapeutics, Inc. (NASDAQ:CYTX) has declined 65.60% since January 13, 2017 and is downtrending. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

A trend analysis is a method of analysis that allows traders to predict what will happen with a stock in the future. The Stock has YTD (year to date) performance of 26.23 percent.

While looking at the Stock's Performance, Cytori Therapeutics, Inc. now shows a Weekly Performance of 40.74%, where Monthly Performance is 52.28%, Quarterly performance is -31.42%, 6 Months performance is -66.9% and yearly performance percentage is -75.75%.

The shares of the company (CYTX) staged the smart recovery as has roared back some 77.07% after stumbling to its new 52-weeks low.

Other reports by Iphone Fresh

Discuss This Article